Company news

Kura Oncology, Inc. news in 2022

Kura Oncology, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

December 9, 2022

Kura Oncology to Host Investor Event on December 10, 2022

November 30, 2022

Kura Oncology Reports Third Quarter 2022 Financial Results

November 2, 2022

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

November 2, 2022

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

November 2, 2022

Kura Oncology to Report Third Quarter 2022 Financial Results

October 26, 2022

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

October 25, 2022

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

August 31, 2022

Kura Oncology Reports Second Quarter 2022 Financial Results

August 2, 2022

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

August 1, 2022

Kura Oncology to Report Second Quarter 2022 Financial Results

July 26, 2022

Kura Oncology Reports First Quarter 2022 Financial Results

May 3, 2022

Kura Oncology to Report First Quarter 2022 Financial Results

April 26, 2022

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

April 7, 2022

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

March 7, 2022

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

February 9, 2022

Kura Oncology Expands Leadership Team with Key Promotions

January 31, 2022

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

January 19, 2022

Calls in 2022

Decks in 2022

  • ASH 2022

    Conference · 18 slides · November 2022